aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
© aVenture Investment Company, 2025. All rights reserved.
44 Tehama St, San Francisco, CA 94105
Privacy Policy
aVenture Investment Company ("aVenture") is an independent venture capital research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals.
While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision.
aVenture does not offer investment advisory services and is not registered as an investment adviser. The data provided by aVenture does not constitute recommendations or advice, whether by methodology or a statement written by a staff member of aVenture.
Links to external websites do not imply endorsement or affiliation with aVenture. References or links to providers offering the ability to invest in a primary or secondary transaction in a company are for convenience purposes only. They are not solicitations or offers to buy or sell an investment. Remember that past performance does not guarantee future results, and venture capital and private assets should be a contributory part of a diversified portfolio.
Founded with a mission to revolutionize cancer treatment, Mythic Therapeutics focuses on developing advanced Antibody Drug Conjugates (ADCs) using their proprietary FateControl™ technology. This innovative platform enhances the precision of ADCs, ensuring that chemotherapy is delivered directly to cancerous cells while sparing healthy tissues. By increasing the efficacy and reducing the toxicity of cancer treatments, Mythic Therapeutics aims to provide more effective and safer therapeutic options for a wide range of cancer types.
Notable figures associated with Mythic Therapeutics include experts in oncology and biotechnology, supported by a robust network of investors committed to advancing cancer treatment. The company has achieved significant milestones, including the successful development and application of FateControl™ technology, which has shown promising results in preclinical studies. Mythic Therapeutics' impact lies in its potential to transform the landscape of cancer therapy, offering hope for more targeted and less harmful treatment options.
Operating Status
Active
Ownership Type(s)
Venture Capital, Private Equity
Main Product(s)
Antibody Drug Conjugates
Technology
Biotech
Tags
Biotech, Healthtech
Model Types
Platform
Revenue Type(s)
Recurring
Customer Type(s)
Enterprise
Geographic Exposure
Global
When was Mythic Therapeutics founded?
Mythic Therapeutics was founded in 2017.
Where is Mythic Therapeutics's headquarters located?
Mythic Therapeutics's headquarters is located in Waltham, MA, US.
When was Mythic Therapeutics's last funding round?
Mythic Therapeutics's most recent funding round was for $103M (USD) in December 2021.
How many employees does Mythic Therapeutics have?
Mythic Therapeutics has 46 employees as of Feb 5, 2024.
How much has Mythic Therapeutics raised to-date?
As of July 05, 2023, Mythic Therapeutics has raised a total of $126.6M (USD) since Dec 15, 2021.
Add Comparison
Total Raised to Date
$126.6M
USD
Last Update Dec 15, 2021
Last Deal Details
$103M
USD
Dec 15, 2021
Series B
Total Employees Over Time
46
As of Feb 2024
Mythic Therapeutics Address
100 Beaver Street
Waltham,
Massachusetts
02453
United States
Source(s): This page includes data and analysis provided by the company, OpenAI, and our research analysts